| Literature DB >> 30872748 |
Essam J Alyamani1, Sarah A Marcus2, Sarah M Ramirez-Busby3, Chungyi Hansen2, Julien Rashid2, Amani El-Kholy4, Daniel Spalink5, Faramarz Valafar3, Hussein A Almehdar6, Asif A Jiman-Fatani7, Mohamed A Khiyami1, Adel M Talaat8.
Abstract
Tuberculosis (TB) represents a significant challenge to public health authorities, especially with the emergence of drug-resistant (DR) and multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis. We sought to examine the genomic variations among recently isolated strains of M. tuberculosis in two closely related countries with different population demography in the Middle East. Clinical isolates of M. tuberculosis from both Egypt and Saudi Arabia were subjected to phenotypic and genotypic analysis on gene and genome-wide levels. Isolates with MDR phenotypes were highly prevalent in Egypt (up to 35%) despite its relatively stable population structure (sympatric pattern). MDR-TB isolates were not identified in the isolates from Saudi Arabia despite its active guest worker program (allopatric pattern). However, tuberculosis isolates from Saudi Arabia, where lineage 4 was more prevalent (>65%), showed more diversity than isolates from Egypt, where lineage 3 was the most prevalent (>75%). Phylogenetic and molecular dating analyses indicated that lineages from Egypt were recently diverged (~78 years), whereas those from Saudi Arabia were diverged by over 200 years. Interestingly, DR isolates did not appear to cluster together or spread more widely than drug-sensitive isolates, suggesting poor treatment as the main cause for emergence of drug resistance rather than more virulence or more capacity to persist.Entities:
Mesh:
Year: 2019 PMID: 30872748 PMCID: PMC6418154 DOI: 10.1038/s41598-019-41162-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient demographics information for both Egypt and Saudi Arabia.
| Egypt | Saudi Arabia | |||
|---|---|---|---|---|
| Count | Percent* | Count | Percent* | |
| <11 | 0 | 0% | 6 | 10% |
| 11–20 | 1 | 2.90% | 9 | 15% |
| 21–40 | 18 | 52.90% | 30 | 49% |
| 41–60 | 10 | 29.40% | 9 | 15% |
| >60 | 5 | 14.70% | 7 | 11% |
| Male | 29 | 85.30% | 27 | 44% |
| Female | 5 | 14.70% | 34 | 56% |
| Egyptian | 34 | 100% | 0 | 0 |
| Saudi | 21 | 34% | ||
| Somali | 15 | 25% | ||
| Yemeni | 7 | 11% | ||
| Chadian | 4 | 7% | ||
| Pakistani | 3 | 5% | ||
| Afghan | 2 | 3% | ||
| Ethiopian | 2 | 3% | ||
| Filipino | 2 | 3% | ||
| Indonesian | 2 | 3% | ||
| Indian | 1 | 2% | ||
| Malian | 1 | 2% | ||
| Burmese | 1 | 2% | ||
| Greater Cairo, Egypt | 23 | 67.60% | ||
| Fayoum, Egypt | 11 | 32.40% | ||
| Asir, Saudi Arabia | 1 | 2% | ||
| Jeddah, Saudi Arabia | 46 | 75% | ||
| Makkah, Saudi Arabia | 3 | 5% | ||
| Unknown city within Saudi Arabia | 11 | 18% | ||
*Percentages are calculated based on the total number of isolates (N = 95) that were cultured from sputum samples received from both Egypt (N = 34) and Saudi Arabia (N = 61).
Drug resistance profile of analyzed M. tuberculosis isolates from Egypt and Saudi Arabia.
| Acid Fast Bacilli (AFB)* | Egypt | Saudi Arabia | ||
|---|---|---|---|---|
| Number** | Percent** | Number** | Percent** | |
| No AFB seen | 1 | 2.90% | 15 | 25% |
| 1–9 AFB | 11 | 32.40% | 15 | 25% |
| + | 15 | 44.10% | 10 | 16% |
| + + | 7 | 20.60% | 7 | 11% |
| +++ | 10 | 16% | ||
| Inconclusive | 4 | 7% | ||
| Isoniazid | 12 (2) | 35.3% (5.9%) | 1 | 1.6% |
| Ethambutol | 13 (0) | 34.2% (0) | 3 (0) | 4.9% (0%) |
| Pyrazinamide | 0 | 0 | 3 | 5% |
| Streptomycin | 3 | 8.80% | 4 (3) | 6.5% (5%) |
| Rifampicin | 13 (4) | 34.2% (11.8%) | 0 | 0% |
| Pan-sensitive | 2 (22) | 5.9% (64.7%) | 52 (55) | 85.2 (90.1%) |
| Double DR (ET, S) | 0 | 0.00% | 2 (0) | 3.3% (0%) |
| MDR (INH, ET, R) | 12 (2) | 35.3% (5.9%) | 0 | 0 |
| MDR (INH, S, R, PZ, ET) | 2 | 5.90% | 0 | 0 |
*Scores represent the level of acid fast bacilli (AFB) in each sample.
>10 AFB/field in 20+ fields:+++.
1–10 AFB/field in 50+ fields:++.
10–99 AFB/ 100 fields: +.
1–9 AFB/100 fields: 1–9.
0 AFB/ 300 fields: No AFB seen.
**Where they differ from UW-Madison laboratory testing, Original numbers and percentages reported from clinical laboratories are listed in parenthesis
***S: streptomycin, R: rifampicin, INH: isoniazid, PZ: pyrazinamide, ET: ethambutol, MDR: multi-drug-resistant.
Figure 1Lineage distribution based on MIRU-VNTR typing for isolates from both (A) Egypt and (B) Saudi Arabia. If a conflict of lineage assignment occurred, PCR tests were performed to assign the appropriate lineage.
Lineage differences between two databases of KSA and Egypt samples.
| Lineage 1 | Lineage 2 | Lineage 3 | Lineage 4 | Others* | Total | |
|---|---|---|---|---|---|---|
| KSA TBinsight | 4 | 5 | 8 | 44 | 0 | 61 |
| KSA MIRU-VNTRplus | 3 | 1 | 9 | 41 | 7 | 61 |
| Egypt TBinsight | 5 | 0 | 25 | 3 | 0 | 33 |
| Egypt MIRU-VNTRplus | 5 | 0 | 21 | 7 | 0 | 33 |
*Samples not assigned to lineages 1, 2, 3, or 4.
Figure 2Percentage of synonymous SNPs (sSNP), non-synonymous SNPs (nSNP) and SNPs located in intergenic areas (intergenic). SNPs were included if coverage was more than 20 reads and frequency was ≥50% of the reads.
Figure 3Evolutionary relationships and divergence dates of isolates from Egypt and Saudi Arabia. Divergence dates are in years, with the 95% confidence intervals of node ages represented by blue bars. The topology was recovered with 100% posterior probability, except for those nodes labeled. Color coded boxes at the tips indicate the nationality of the patient from which the sample was isolated and correspond with the color of countries mapped in Fig. 4. SA tip labels refer to samples isolated in Saudi Arabia, whereas E tip labels refer to those isolated in Egypt.
Figure 4Geographical maps of M. tuberculosis drug-resistant isolates examined in this study. (A) A map of Egypt with an inset pie chart describing percentages of drug-resistant phenotypes among Egyptian isolates with whole sequenced genomes (N = 19). Note the sum of all percentages >100% because of the high levels of MDR among Egypt isolates. (B) A map showing the countries of origin for patients examined in Saudi Arabia. The inset pie chart describing percentages of drug-resistant phenotypes among Saudi Arabian isolates with whole sequenced genomes (N = 30).